Flamingo-TRA: Vaginal Micronized Progesterone for the Prolongation of Pregnancy after Arrested Preterm Labor
Source: View publication →
In this randomized clinical trial of women with arrested preterm labor, daily vaginal micronized progesterone did not significantly reduce the rate of subsequent spontaneous preterm delivery compared to no treatment.
Key Findings
Study Design
Study Limitations
Clinical Significance
The results do not support the routine use of vaginal micronized progesterone specifically for the purpose of prolonging pregnancy in the setting of arrested preterm labor, distinguishing this clinical scenario from the established use of progesterone in women with a short cervix or prior history of spontaneous preterm birth.
Historical Context
Progesterone has been a cornerstone in preterm birth prevention strategy, with strong evidence supporting its efficacy for singleton pregnancies with sonographically short cervices or a history of preterm birth. However, its utility in other high-risk scenarios, such as arrested preterm labor or multiple gestations, has remained controversial, with previous meta-analyses and trials showing inconsistent results for these specific populations.
Guided Discussion
High-yield insights from every perspective
What is the physiological rationale for using progesterone to prevent preterm birth, and why might its efficacy diminish once a patient has already entered 'arrested preterm labor' (APTL)?
Key Response
Progesterone is vital for maintaining uterine quiescence by inhibiting the production of pro-inflammatory cytokines and prostaglandins, and downregulating oxytocin receptors. However, in APTL, the inflammatory cascade and 'functional progesterone withdrawal' at the receptor level have often already been triggered; the Flamingo-TRA study suggests that exogenous supplementation at this late stage cannot reliably reverse the pathway to delivery.
The Flamingo-TRA trial compared vaginal progesterone to no treatment in women with arrested preterm labor. How do these findings influence the clinical decision to initiate maintenance therapy after a patient has been successfully tocolyzed?
Key Response
The trial found no significant difference in the rate of spontaneous preterm delivery (sPTD) between the progesterone group and the no-treatment group. For residents, this reinforces the principle that 'maintenance tocolysis' or hormonal therapy after an acute episode of preterm labor is generally not evidence-based, and clinicians should resist the urge to prescribe progesterone for this specific indication, even if the patient has a short cervix.
In the context of the Flamingo-TRA trial and the controversy surrounding the PROLONG trial (which led to the withdrawal of 17-OHPC), how should we interpret the failure of vaginal progesterone in the 'arrested preterm labor' population compared to its efficacy in 'asymptomatic short cervix' populations?
Key Response
The failure in Flamingo-TRA highlights a critical distinction between primary prevention (asymptomatic short cervix) and secondary maintenance (post-acute labor). Fellows should recognize that the 'arrested' state likely represents a different biochemical phenotype where the risk is no longer primarily driven by cervical mechanical failure, but by a systemic or local inflammatory process that is no longer responsive to supplemental progesterone.
Given that Flamingo-TRA was an open-label trial that failed to show benefit, how do you balance the 'do no harm' principle with the psychological pressure to provide an intervention for a high-risk patient who has just survived an acute preterm labor episode?
Key Response
This is a key teaching point on de-implementation. The trial provides high-quality evidence that vaginal progesterone does not improve outcomes in this cohort. Attendings should use these data to educate patients and staff that unnecessary medicalization increases cost and patient burden without neonatal benefit, effectively shifting the focus from 'doing something' to 'doing what works.'
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Flamingo-TRA was terminated early due to slow recruitment, reaching only 300 of the planned 494 participants. How does this underpowering affect the fragility of the null result, and what statistical approaches could be used to determine if the trial still holds sufficient evidence to stop further research into this indication?
Key Response
Underpowered trials risk a Type II error. However, a PhD candidate would analyze the 'Conditional Power' or the 'Bayesian Predictive Probability' of reaching a significant result if the trial had continued to full enrollment. If the observed effect size is sufficiently small, one can argue that the probability of the trial ever reaching significance is negligible, thereby justifying the conclusion despite the smaller sample size.
As a reviewer, the lack of a placebo group (no treatment vs. progesterone) is a significant design choice. How might this lack of blinding have biased the primary outcome of spontaneous preterm delivery (sPTD) and the secondary outcome of maternal anxiety?
Key Response
The lack of a placebo can lead to performance bias. Patients in the 'no treatment' group might have been more likely to restrict activity or seek additional medical care out of anxiety, whereas those on progesterone might have had a false sense of security. An editor would flag that while sPTD is an objective outcome, the decision to present to the hospital for 'perceived' labor is subjective and influenced by the knowledge of treatment status.
Current ACOG and SMFM guidelines primarily recommend vaginal progesterone for asymptomatic women with a short cervix. How does the Flamingo-TRA trial fill a 'gap' in current guidelines regarding maintenance therapy, and should a formal recommendation against progesterone for APTL be issued?
Key Response
Existing guidelines (like ACOG Practice Bulletin 171) focus on prevention rather than maintenance. Flamingo-TRA provides specific Level 1b evidence that vaginal progesterone is ineffective for the APTL population. A guideline committee might use this to issue a 'Strong Recommendation' against its use in this context to prevent the common clinical practice of 'indication creep,' where providers apply prophylactic evidence to an acute/maintenance scenario.
Clinical Landscape
Noteworthy Related Trials
Fingertip Study
Tested
Vaginal progesterone 200mg daily
Population
Women with short cervix identified on ultrasound
Comparator
Placebo
Endpoint
Preterm birth less than 34 weeks
OPPTIMUM Trial
Tested
Vaginal progesterone 200mg daily
Population
Women at risk of preterm birth
Comparator
Placebo
Endpoint
Composite of perinatal death, neonatal brain injury, or survival with impairment at 2 years
PREGVAIL Trial
Tested
Vaginal progesterone 200mg daily
Population
Women with prior spontaneous preterm birth
Comparator
Placebo
Endpoint
Preterm birth before 34 weeks gestation
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis